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lthough scientists have postulated a wide range
of adverse human health effects of exposure to
endocrine-disrupting chemicals (EDCs), the
nexus of the debate is the concern that prenatal and
childhood exposure to EDCs may be responsible for a
variety of abnormalities in human sexuality, gender
development and behaviors, reproductive capabilities,
and sex ratios. Scientists today are asking hard ques-
tions about potential human effects: Do EDC expo-
sures impair fertility in men or women? Can they cause
sexual organ malformations, stunted reproductive
development, or testicular or breast cancer? Do fetal
exposures to EDCs alter sex phenotypes? Do they
change later gender-related neurobiological characteris-
tics and behaviors such as play activity and spatial abil-
ity? Could such exposures even be involved in the eti-
ology of children born with ambiguous gender?
EDCs include a spectrum of substances that can
be loosely classified according to their known or sus-
pected activity in relation to sex hormone receptors
and pathways. The most-studied and best known are
the environmental estrogens, which mimic estradiol
and bind to estrogen receptors (ERs). ER agonists
include the pesticide methoxychlor, certain polychlo-
rinated biphenyls (PCBs), bisphenol A (BPA; a high
production volume chemical used to make polycar-
bonate plastic), pharmaceutical estrogens such as
diethylstilbestrol (DES) and ethinyl estradiol, and
phytoestrogens, which occur naturally in many
plants, most notably in soybeans in the form of genis-
tein and related substances. There are a few known
ER antagonists, or antiestrogens. Antiandrogens, or
androgen receptor (AR) antagonists, include the fun-
gicide vinclozolin, the DDT metabolite p,p´-DDE,
certain phthalates (a group of chemicals used to soft-
en polyvinyl chloride plastics), and certain other
PCBs. And there are other types of EDCs that affect
particular endocrine targets. The various EDCs differ
greatly in their potencies relative to natural hor-
mones, and in their affinity for target receptors.
Some have been shown to act via non–receptor-
mediated mechanisms, for example by interfering
with hormone synthesis.
In many well-documented cases of high-level fetal
exposures to known EDCs such as DES, certain
PCBs, and DDT, the answer to the question of
whether exposure is associated with gender-related
effects is clearly yes. But high-level exposures such as
these are relatively rare and isolated. The debate today
centers on low-dose exposures—generally defined as
doses that approximate environmentally relevant lev-
els—and the idea that low-dose intrauterine exposure
to some EDCs during certain critical windows of
development can have profound, permanent impacts
on subsequent fetal development and adult outcomes. 
Critics of this idea maintain that thus far there is
no credible evidence to suggest that low-dose expo-
sures cause any adverse human health effects. But if
low-dose exposures were confirmed to be the threat
that proponents of the concept insist they are, public
health would clearly be at risk, regulatory agencies’
risk assessment approach would need to be revised,
and certain common chemicals—including some that
are massively produced and economically impor-
tant—would likely disappear from the marketplace.
In a June 2000 EHP review article on human
health problems associated with EDCs, Stephen Safe,
director of the Center for Environmental and Genetic
Medicine at Texas A&M University, concluded that
“the role of endocrine disruptors in human disease has
not been fully resolved; however, at present the evi-
dence is not compelling.” Frederick vom Saal, a devel-
opmental biologist at the University of Missouri–
Columbia, disagrees, particularly in light of the
research that’s been presented in the years since that
review. “The jury is not out on human effects,” he
says. “In terms of the amount of information we have
in animals and the amount of information we have in
humans, clearly there is a huge difference, but that’s a
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EDCs influence humans.” One thing both
scientists might agree on, though, is that
right now there are still more questions than
answers.
A Delicate Process
The endocrine system, comprising the hypo-
thalamus, pituitary, testes, ovaries, thyroid,
adrenals, and pancreas, is one of the body’s
key communications networks. It regulates
the function of specific tissues and organs by
secreting hormones that act as precise chemi-
cal messengers. Development and regulation
of the reproductive system is one of the major
functions of the endocrine system.
Sex determination and development
begin early in gestation, with the differenti-
ation of the embryonic gonad into either
testes or ovaries. If the Sry gene is present on
the Y chromosome, it will, when activated,
trigger a complex cascade of hormonal
events that ultimately results in the birth of
a baby boy with all of the requisite male
equipment in place and functioning proper-
ly. In the absence of the Sry gene, the end
product of the process will be a baby girl.
The female phenotype is considered to be
the “default” pathway for mammalian repro-
ductive development. 
Differentiation and development of the
sexual organs continues throughout gestation
under the guidance of the various sex hor-
mones (such as estrogen and testosterone)
produced by the endocrine system. For males
and females alike, the entire process of repro-
ductive development is exquisitely sensitive to
minute changes in levels of the sex hormones,
particularly during certain critical windows of
development. 
In papers published in the Journal of
Animal Science throughout 1989, vom Saal
demonstrated this sensitivity in a series of
mouse experiments. These studies showed
that in multiple-birth species it was possible
for adjacently positioned male and female
fetuses to transmit tiny amounts of hormones
to each other, with pronounced phenotypic
consequences. “We found that a difference of
about a part per billion of testosterone and
about twenty parts per trillion of estradiol
[endogenous estrogen] actually predict entire-
ly different brain structures, behavioral traits,
enzyme levels, and receptor levels in tissues,
hormonal levels in the blood—there is noth-
ing you look for that . . . doesn’t differ in these
animals,” says vom Saal.
Such a delicately timed and precisely
controlled process presents a myriad of
opportunities for perturbation from expo-
sure to EDCs. These chemicals mimic hor-
mones, and can disrupt differentiation and
development in a wide variety of ways, by
duplicating, exaggerating, blocking, or alter-
ing hormonal responses. The developing
fetus and early neonate may lack the protec-
tive metabolic mechanisms present in adults
that help detoxify and break down chemicals,
maintaining homeostasis in the system. Also,
tissues are rapidly dividing and differentiat-
ing in the fetus, and such a high level of cell
activity is vulnerable to disruption of normal
development. With such small body mass in
the fetus and child compared to an adult,
exposure levels may be amplified in terms of
relative dosages reaching target tissues. And
sometimes, exogenous EDCs may show very
low binding to plasma hormone-binding
proteins and thus roam the body in an
unbound state, with unknown effects.
Much of what remains to be discovered
about the impacts of EDC exposures on the
fetus relates to a new concept called the devel-
opmental origins of health and disease (until
recently known more commonly as the fetal
basis of adult disease). “People are just now
recognizing that this is indeed a possibility,”
says NIEHS scientist Retha Newbold, a pio-
neer in the study of endocrine disruption
who has spent decades researching the effects
of exogenous estrogens, particularly DES.
“Developmental exposure to low doses of
EDCs may not lead to malformation or to
anything you can look at and immediately
recognize as a problem,” she says. “But it still
could have long-term effects, such as alter-
ations in metabolism, alterations causing can-
cer later on, or alterations causing infertility.”
Evidence of Effects
Reproductive and developmental abnormali-
ties linked to EDC exposures have now been
documented in birds, frogs, seals, polar bears,
marine mollusks, and dozens of other wildlife
species. For example, alligators in Lake
Apopka—one of Florida’s most polluted lakes
due to extensive farming activities around the
lake, the presence of a sewage treatment facil-
ity, and a major 1980 spill of pesticides
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Watching wildlife. Research has documented reproductive
and developmental abnormalities linked to EDC exposures in
wildlife species such as alligators and polar bears, although
what these results mean for humans is still unknown.including DDT and DDE—have been
shown to have been “feminized.” That is,
zoologist Louis J. Guillette, Jr., and colleagues
first reported in the August 1994 EHP, the
males have shortened penises and low levels
of testosterone, while the females have exces-
sive levels of estrogens. Sex reversal (in which
an animal of one sex matures with the repro-
ductive organs and capabilities of the other
sex) and skewed sex ratios (in which there is
an unusually greater proportion of one sex
than the other) have been seen in several fish
populations, particularly colonies living in
close proximity to pulp and paper mills and
sewage treatment plants. Other reports have
shown reproductive effects among wildlife
resulting from exposure to EDCs excreted
into the water supply by women taking birth
control pills. 
Many of the adverse outcomes seen in
wildlife populations have been replicated in
laboratory experiments, confirming the role of
EDCs in their occurrence. Among the papers
reporting such confirmation were a May 1997
article in EHP, in which Guillette, D. Andrew
Crain, and colleagues replicated alterations in
steroidogenesis (the production of sex hor-
mones) in alligators. More recently, in the
December 2004 issue of EHP, Jon Nash and
colleagues showed that long-term laboratory
exposure to environmental concentrations of
the pharmaceutical ethinyl estradiol caused
reproductive failure in zebrafish.
According to a report on EDCs pub-
lished in volume 75, issue 11/12 (2003) of
Pure and Applied Chemistry by the Scientific
Committee on Problems of the Environ-
ment/International Union of Pure and
Applied Chemistry (SCOPE/IUPAC), more
than 200 animal species are either known or
suspected to have been affected by these
chemicals. “The weight of evidence for
endocrine disruption in wildlife is really
overwhelming,” says Joanna Burger, a pro-
fessor of cell biology and neuroscience at
Rutgers University who cochaired the
SCOPE/IUPAC project. 
The SCOPE/IUPAC report was less
definitive on the extent of human effects of
endocrine disruptors. “It is too early to reach
firm conclusions about whether human pop-
ulations are seriously at risk from potential
exposures to [EDCs], and further vigilance is
clearly required,” the authors wrote. “How-
ever, it is somewhat reassuring that after sub-
stantial research in the past decade, there have
been no conclusive findings of low-level envi-
ronmental exposures to [EDCs] causing
human disease.”
The report further notes, however, that
“[c]hemical interferences with steroid biosyn-
thesis and metabolism can produce adverse
health effects, even though the inducing
agent would not be detected as an [EDC]
using receptor-based test systems. This is an
important area of study because some exam-
ples of [endocrine disruption] occurring in
animals derive from exposure to inhibitors of
steroidogenic enzymes such as 5α-reductase
and aromatase. Some such agents are known
to be active in humans and are used success-
fully in the treatment of a range of human
hormonal conditions.” The authors suggested
that evaluation of such effects will require
integrated screening that incorporates in vitro
and in vivo technologies.
A comprehensive report issued in 2002
by the World Health Organization’s Inter-
national Programme on Chemical Safety,
titled  Global Assessment of the State-of-the-
Science of Endocrine Disruptors, reached simi-
lar conclusions. The report stated that
“although it is clear that certain environmen-
tal chemicals can interfere with normal hor-
monal processes, there is weak evidence that
human health has been adversely affected by
exposure to endocrine-active chemicals.
However, there is sufficient evidence to con-
clude that adverse endocrine-mediated
effects have occurred in some wildlife
species.” Citing the fact that studies to date
examining EDC-induced effects in humans
have yielded inconsistent and inconclusive
results, the group wrote that, although that
explains their characterization of the evi-
dence as weak, “[that] classification is not
meant to downplay the potential effects of
EDCs; rather, it highlights the need for more
rigorous studies.”
The Global Assessment further states that
the only evidence showing that humans are
susceptible to EDCs is currently provided by
studies of high exposure levels. There is, in
fact, clear evidence that intrauterine EDC
exposures can alter human reproductive tract
development and physiology. The most thor-
oughly characterized example is DES, the
synthetic estrogen prescribed to millions of
pregnant women in the United States and
elsewhere from the 1940s to the 1970s to pre-
vent miscarriage. The drug is known to have
caused a rare form of vaginal cancer in thou-
sands of daughters of women who took DES,
as well as a variety of adverse reproductive
tract effects in both the daughters and sons of
those women.
The DES situation could be seen as a
worst-case scenario for prenatal EDC expo-
sure—the deliberate delivery of a potent estro-
genic chemical in high doses. Viewed another
way, it has provided researchers a rare opportu-
nity to study the effects of prenatal EDC expo-
sure in a relatively controlled fashion, with a
well-defined population and well-characterized
exposure to a single potent agent.
Over the course of her research, Newbold
has developed a mouse model of DES expo-
sure that has proven extremely useful in
studying the effects of DES and other envi-
ronmental estrogens, particularly those out-
comes that may be manifested only later in
life. “With the experimental model, there are
a lot of questions we can ask with DES that
will tell us about the weaker environmental
estrogens,” she says. “We can change the tim-
ing of exposure and the amount of exposure,
and we can look at different target tissues.” 
The animal model has replicated numer-
ous abnormalities reported in DES-exposed
humans, and has also predicted some human
outcomes. “We have published documenta-
tion [see, for example, the October 1985
issue of Cancer Research and volume 5, issue 6
(1985) of Teratogenesis, Carcinogenesis, and
Mutagenesis] that a number of the reproduc-
tive anomalies seen in DES-exposed mice,
such as retained testes and abnormalities in
the oviduct in females, were also later report-
ed in DES-exposed humans,” says Newbold. 
The Phthalate Connection
But reliable correlations between animal data
and human outcomes have proven elusive,
particularly when it comes to showing an
association between human exposures to
environmental EDCs at ambient levels (that
is, unrelated to spills or other acute contami-
nation events) and adverse health effects.
That may be about to change for one class of
chemicals—phthalates.
Phthalates are commonly used in a wide
variety of consumer products such as solvents,
soft plastics, and cosmetics. The National
Health and Nutrition Examination Survey
showed that the majority of the U.S. popula-
tion carries a measurable body burden of sev-
eral phthalates. There is an extensive body of
literature regarding the effects of prenatal
phthalate exposure in rodents. Those effects
include an association between intrauterine
exposure and abnormalities in male animals
in a biomarker known as anogenital distance
(AGD), or the distance between the rectum
and the base of the penis. AGD has been
shown to be a sensitive measure of prenatal
antiandrogen exposure. This pattern of geni-
tal dysmorphology has come to be known as
the “phthalate syndrome.”
In the first study to look at the link
between AGD and EDC exposure in
humans, Shanna Swan, a professor of obstet-
rics and gynecology at the University of
Rochester, and her colleagues collected data
from 85 mother–son pairs participating in
the Study for Future Families, a multicenter
pregnancy cohort study. The mothers’ urine
was analyzed for the presence of several
phthalate metabolites, and the infant boys,
aged 2–36 months, were examined for genital
developmental characteristics, including
AGD, which was standardized for weight to
develop an anogenital index (AGI). 
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of frank genital malformations or disease,
they did discover an association between ele-
vated concentrations of four phthalate
metabolites in the mothers and shorter-than-
expected AGI in the infants, as reported in
the August 2005 issue of EHP. And, impor-
tantly, shortened AGI was found in infants
exposed prenatally to phthalate metabolites
at concentrations comparable to those found
in one-quarter of the U.S. female popula-
tion. The boys with short AGI were also sig-
nificantly more likely to have incomplete
testicular descent (cryptorchidism). “We
know that incomplete testicular descent is
a risk factor for poorer semen quality,
lower sperm counts, [impaired fertility],
and testicular cancer,” says Swan. Although
it is obviously impossible to predict adult
outcomes, she says these infants may be at
risk of testicular dysgenesis syndrome
(TDS) in the future.
TDS is a concept put forth by Danish
researcher Niels Skakkebæk and colleagues,
in which four adverse male reproductive end
points—impaired semen quality, crypt-
orchidism, hypospadias (abnormal location
of the urethra), and testicular cancer—are
risk factors for each other. Says Swan, “The
idea is that the development of the testis is
interrupted in fetal life, and that this has
consequences in adult life, as well as at birth.
That certainly is something we’ve seen in
rodents, and this study is the first evidence
we’ve seen of TDS in humans.”
Swan’s study is among the first to combine
a population-based, measurable, low-level
EDC exposure, observed physiologic effects,
and solid biological underpinnings. Even
skeptic Safe says that this is the kind of study
needed to begin to answer the many questions
about EDCs and human health. “This looks
to be a good approach, and suggests a correla-
tion,” he says. “Whether it’s causal of anything
and whether it holds up or not, I don’t know.
It needs to be repeated in different locations
and with more and more integrated measure-
ments.” Swan plans to do just that, as well as
to follow up on her current pregnancy cohort
by measuring gender role behaviors in both
the male and female children, who are now
between 2 and 5 years old.
The Phthalate Esters Panel of the
American Chemistry Council, a trade organ-
ization based in Arlington, Virginia, main-
tains that “there is no well-established and
credible evidence for adverse effects [due to
phthalates] in humans at environmentally
relevant doses,” says panel manager Marian
Stanley. With regard to Swan’s study, Stanley
says, “It correlated some effects in infant
males with some lower-molecular-weight
phthalates, particularly diethyl phthalate, for
which effects in rodents occur only at very
high doses, and which is not considered to
pose reproductive or developmental concerns
by reviewing government agencies.” 
Stanley also points to questions about the
biomarker used in the study. “The measure-
ment that was used is something that I think
is still subject to debate. You see the AG dis-
tance in rodents, and while it is a marker of
something, it is certainly not a biological
effect,” she says. “I think the study has been
overinterpreted by lots of other people
[besides] the authors of the study.”
EDCs and Sex Ratios
Sex ratio—the proportion of male to female
live births—is very constant on a worldwide
basis, typically ranging from 102 to 108 male
births for every 100 female births. In recent
years, however, a number of reports have sug-
gested that environmental and occupational
exposures to EDCs may be altering the sex
ratio within given human populations. 
In one such study, appearing in the July
2005 edition of Human Reproduction, a
group of Swedish researchers analyzed blood
and semen samples from 149 fishermen to
investigate whether exposure to the persistent
organochlorine pollutants CB-153 (a PCB)
and p,p´-DDE affected the proportion of Y-
and X-chromosome-bearing sperm. They dis-
covered that elevated exposure levels of both
chemicals were positively associated with a
higher proportion of Y-chromosome sperm.
The researchers conclude that their findings
add to evidence that exposure to persistent
organic pollutants may alter the offspring sex
ratio, with the higher proportion of Y-
chromosome sperm likely tending to lead to
a higher proportion of male births.
A study appearing in the October 2005
issue of EHP takes an epidemiologic
approach to the issue. Constanze Mackenzie,
a member of the Faculty of Medicine at the
University of Ottawa, and colleagues report a
distinct skewing of the sex ratio within mem-
bers of the Aamjiwnaang First Nation com-
munity near Sarnia, Ontario. They found a
severe decline in the proportion of boys born
among the Aamjiwnaang over the last five
years, and a lesser though still significant
decline over the past ten years. Although no
causal factors were determined, the authors
note that the community is located in imme-
diate proximity to several large petrochemi-
cal, polymer, and chemical plants, and that
previous studies—such as those following the
1976 industrial accident in Seveso, Italy—
have shown that exposure to contaminants
such as EDCs can impact sex ratios within
small communities near such industrial facil-
ities. The authors suggest that further assess-
ment should be pursued to identify potential
exposures among community members. [For
more details on this study, see “Shift in Sex
Ratio,” p. A686 this issue.]
How Low Do They Go?
When is a hypothesis no longer a hypothesis,
but a validated scientific concept ready to
drive regulatory and policy decision making?
When it comes to the so-called “low-dose
hypothesis” regarding the biological activity or
adverse effects of low-dose exposures to
EDCs, that is the key question. The issue has
been debated for years, since vom Saal’s group
first published in the January 1997 issue of
EHP their findings of enlarged prostate in
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A question of Y. A Swedish study of fishermen exposed to CB-153 and p,p´-DDE associated
elevated levels of these chemicals with a higher proportion of Y-chromosome sperm, suggesting
that exposure to EDCs could skew the ratio of boys to girls.Environmental Health Perspectives • VOLUME 113 | NUMBER 10 | October 2005 A 675
male mice whose mothers
had been fed low doses of
BPA. Today, the controversy
over whether vom Saal’s find-
ings have been sufficiently
replicated, and whether the
U.S. Environmental Protec-
tion Agency (EPA) should
revise its risk assessment
process to reflect the poten-
tial for adverse effects of low-
dose EDCs, is still going
strong.
Some proponents of the
low-dose hypothesis argue
that the traditional toxico-
logic approach to risk assess-
ment is an inappropriate
method to assess EDCs. The
current protocol assumes a
linear dose-dependent re-
sponse to chemical expo-
sures, determines the lowest
level at which there is an
observed adverse effect, and
then adds a safety factor to
arrive at an official reference
dose—the daily human
intake assumed to be safe.
Experimental work by vom
Saal and others has postu-
lated that EDCs exhibit a
U-shaped dose–response
curve, with biological activ-
ity stimulated at very low
doses—often several orders
of magnitude below current
reference doses—as well as
very high doses.
Proponents also state that the process of
endocrine disruption itself is inherently dif-
ferent from many other toxicologic process-
es, affecting a variety of highly sensitive
pathways (especially in the fetus) via novel
mechanisms of action, many of which are as
yet poorly understood. Also, they say,
endocrine-signaling pathways that mediate
responses to EDCs have evolved to act as
powerful amplifiers, resulting in large changes
in cell function occurring in response to
extremely small concentrations.
One chemical that has become a light-
ning rod in the debate is BPA. By vom Saal’s
count, there are now more than 100 pub-
lished peer-reviewed studies showing signifi-
cant biological effects of low doses of BPA
(almost half published within the last two
years) compared to 21 reporting no effect. He
is convinced that widespread exposure to
BPA poses a threat to human health.
Not so, claims Steve Hentges, executive
director of the Polycarbonate Business Unit
of the American Plastics Council: “For our
purposes, what we have to know is, does BPA
cause health effects in humans at any relevant
dose, particularly at the levels at which people
are actually exposed? When you look at all of
the evidence together, and in particular look
at the comprehensive studies that are
designed to look for health effects, you don’t
find them.” 
The industry group also believes that the
weight of evidence does not support the con-
cept of a low-dose effect for BPA. “And it’s
not just us saying that,” says Hentges.
“Indeed, every government body worldwide
that’s looked at it has reached effectively the
same conclusion in terms of how they regu-
late BPA or consider regulating it.” He
acknowledges that there has been quite a bit
of new research activity in this area within the
past few years, but states that “even though
new research has been conducted, we believe
that the weight of evidence has not shifted.”
Where does the EPA stand on these
issues? The agency’s Office of Research and
Development is in the midst of implement-
ing a multiyear plan to set the EPA’s agenda
and goals in the area of EDC research. The
plan is part of the agency’s Endocrine
Disruptors Research Program, a five- to ten-
year research agenda it started in 2001 to look
comprehensively at the science surrounding
EDC exposures and effects. The integrated
program was launched at about the same time
that a congressional mandate, under the 1996
Food Quality Protection Act, directed the
EPA to develop a screening and testing pro-
gram for EDCs. 
The EPA’s stance is that the jury is still
out on both the public health impacts of
EDCs and the need to incorporate low-dose
methodologies into the agency’s risk assess-
ment protocols. Elaine Francis, director of
the Endocrine Disruptors Research Program,
says the EPA needs to conduct a lot more
research before any definitive public health
statements can be made about this class of
compounds. “When you look at such a
diverse group of organisms that have been
impacted in wildlife, and certainly laborato-
ry rodent species,” she says, “there is enough
concern that we recognize the importance of
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Ubiquitous exposure, unknown consequences. Humans are exposed to EDCs through many routes including phar-
maceuticals, air pollution, pesticides, and drinking water, but the effects of environmental exposure are largely unknown.to characterize any impact [EDCs] might be
having on humans.” 
The agency is currently funding three
research grants in the area of low-dose EDC
exposures, partly in response to the conclu-
sions reached in a 2000 peer review and sub-
sequent report on the low-dose issue held by
the National Toxicology Program at the EPA’s
request. In the 2001 Report of the Endocrine
Disruptors Low-Dose Peer Review, that expert
panel acknowledged that low-dose effects had
been sufficiently documented at that point in
time for the EPA to consider revisiting its cur-
rent testing paradigm. 
“The general consensus was that more
work needed to be done in this area,” says
Francis. “Since that time, we would still agree
that there has not been enough information
to indicate that the existing approaches are
ones that would not be valid for endocrine
disruptors. But we left the door open that we
would need to do more research, and the best
we could do at this point is to support and
promote research in that area, and we’ve
done that.”
Vom Saal is of a different opinion: “In the
risk assessment process for chemicals as cur-
rently conducted, the maximum tolerated
dose is used as a reference, and a span of typ-
ically not more than fiftyfold in the dose
range is the maximum that anyone ever uses
in the studies. Studies [from the 1 January
2005 issue of Cancer Research and the April
2005  EHP show] literally millions of fold
below that dose range in adverse effects . . .
from BPA, and when you have that type of
unbelievable discrepancy, for the EPA to
come out as it recently did and state that it
has no intention of testing low doses as part
of the testing process [implies] that you no
longer have a scientifically based process—it
is an entirely politically driven process,
because they are explicitly ignoring the scien-
tific findings that are out there.”
From her perspective, Newbold feels that
although there is no question that EDCs have
low-dose effects, more research needs to be
done to document adverse effects in humans.
“We spend an awful lot of time arguing
whether there are low-dose effects or not.
That just infuriates me,” she says. “There are
low-dose effects. There have always been low-
dose effects. The question is, are they adverse?
We don’t know, and we’ve got to design stud-
ies to get answers to that question.” She adds,
“In order to take this argument to a whole
other level, we’re going to have to have more
epidemiology studies. I know it happens with
mice, but I don’t know what happens with
humans.” 
Connecting the Gender Dots
It’s premature to call it a theory; at this point,
it barely qualifies as a hypothesis: some
observers are putting forth the proposition
that prenatal EDC exposures may affect gen-
der identity—how a person identifies him- or
herself, regardless of physical characteristics.
This idea presupposes two basic concepts:
first, that transgenderism (in which a person
experiences “gender dysphoria,” a strong feel-
ing of having been born the wrong sex) is
physiological in origin, most likely due to
events during prenatal neurological develop-
ment; second, that intrauterine EDC expo-
sures can and do disrupt prenatal neurological
development.
A paper in the 2 November 1995 issue of
Nature, among other reports, lends credence
to the first concept. Jiang-Ning Zhou and col-
leagues at the Netherlands Institute for Brain
Research studied heterosexual men and
women, homosexual men, and male-to-female
transsexuals. They reported finding a distinct-
ly female brain structure in genetically male
transsexuals (men who had gone through hor-
monal treatment and irreversible sexual reas-
signment surgery to become women). The
volume of the central subdivision of the bed
nucleus of the stria terminalis (BSTc), a sexu-
ally dimorphic brain area that is essential for
sexual behavior, is larger in men than in
women. Anatomical study results showed that
BSTc volume did not differ significantly
between heterosexual and homosexual men,
and that BSTc volume was 44% larger in het-
erosexual men than heterosexual women. In
the male-to-female transsexuals, BSTc volume
was only 52% that of the reference males—a
volume analogous to that seen in the women.
The authors write that these findings “support
the hypothesis that gender identity develops as
a result of an interaction between the develop-
ing brain and sex hormones.”
But a study by Wilson C.J. Chung and
colleagues published in the 1 February 2002
Journal of Neuroscience complicates this pic-
ture. This group, also from the Netherlands
Institute for Brain Research, reported that
BSTc size differentiation between men and
women became significant only in adulthood,
implying that the phenomenon may be more
effect than cause. The authors do point out,
however, that the lack of marked sexual differ-
entiation of the BSTc volume before birth and
in childhood does not rule out early gonadal
steroid effects on BSTc functions. They point
to earlier animal experiments showing that
fetal or neonatal testosterone levels in humans
may first affect synaptic density, neuronal
activity, or neurochemical content during early
BSTc development, and that “[c]hanges in
these parameters could affect the development
of gender identity but not immediately result
in overt changes in the volume or neuronal
number of the BSTc.”
On the other side of the ledger, in the
June 2002 edition of EHP Supplements,
Bernard Weiss, a professor of environmental
medicine and pediatrics at the University of
Rochester, reviewed the existing literature on
sexually dimorphic nonreproductive behav-
iors as indicators of endocrine disruption.
Weiss made a strong evidence-based case that
“gender-specific regional differentiation of
the brain and, ultimately, its expression in
behavior are guided by the gonadal hor-
mones,” and that the process is subject to
interference by drugs and environmental con-
taminants. He points out that sex differences
in performance and behavior are not—but
should be—a recognized criterion in develop-
mental neurotoxicity testing.
So who out there is connecting these dots? 
Scott Kerlin is a Ph.D. social scientist at
the University of British Columbia. He
devotes considerable time to monitoring the
international scientific literature on DES and
other EDCs as well as to researching and writ-
ing about the long-term health effects of pre-
natal DES exposure on males. He is himself
the son of a woman given DES in pregnancy.
Kerlin recently conducted a survey study
of 500 members of the DES Sons Inter-
national Network, an online resource for men
who know or strongly suspect they were
exposed to DES in utero. In a paper present-
ed in August 2005 at the International Behav-
ioral Development Symposium in Minot,
North Dakota, he reports that more than 150
respondents identified themselves as having
any of a variety of gender-related disorders.
Kerlin does not claim that DES causes these
gender disorders, but feels that his results
indicate that such outcomes should be
included in research related to the potential
effects of prenatal EDC exposures.
The Road Ahead
It’s going to be very difficult to ever conclu-
sively answer the basic question of whether
low-level EDC exposures during development
are causing deleterious reproductive or gen-
der-related outcomes in humans. Scientists
agree that one of the major challenges is to
address the issue of mixtures. Typically,
researchers look at the impact of one chemical
at a time, but environmental exposures regu-
larly involve an unpredictable mix of chemi-
cals, with exposures varying widely in dose
and duration. It is unlikely there will ever be a
comprehensive understanding of how the
many EDCs in mixtures interact with each
other and with human physiology.
Convincing epidemiologic evidence of
adverse effects in humans is also difficult to
come by, but will be necessary to translate
scientific findings into concrete actions to
protect public health. Swan’s study, one of
the first of its kind to appear thus far, may
serve as a methodological model for future
investigations of low-level EDC exposures.
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Do we know enough now that steps
should be taken in the policy and regulatory
realm? Some observers, taking a precautionary
approach, think that we do. For example,
there are bills under consideration in the
California and New York legislatures to restrict
the use of certain phthalates in toys, child care
products, and cosmetics, and a California bill
would ban the use of BPA in products meant
for use by children aged 3 years or younger.
Also, the European Parliament voted in 2005
to ban the use of three phthalate plasticizers
(DEHP, di-n-butyl phthalate, and benzyl
butyl phthalate) in toys and child care items,
and to prohibit the use of three others
(diisononyl phthalate, diisodecyl phthalate,
and di-n-octyl phthalate) in toys and child care
items that children can put in their mouths.
Theo Colborn, a professor of zoology at
the University of Florida and author of the
1996 book Our Stolen Future, believes the time
for action is now. “In the animals, it was at the
population level that we really began to realize
what was going on,” she says. “If we’re going
to wait to see population effects for all of these
concerns that we have in the human popula-
tion, it’s going to be too late.” She points out
that we’re already into the fourth generation of
individuals who have been exposed in utero to
chemicals that had never been used before the
mid-1930s or early 1940s.
Swan agrees that there is sufficient knowl-
edge at this point to call EDC exposures a
serious threat to public health. “I don’t think
it’s necessarily a threat to individuals,” she
says, “but I think that as a population we are
threatened. I’m not predicting the end of the
species or anything like that, but I think the
increasingly alarming trends that we’re seeing,
in terms of couples that can’t conceive or cou-
ples whose babies have undescended testicles,
and so on, can have an impact on the popu-
lation as a whole.” 
Other observers are not so sure. Harry
Fisch, director of the Male Reproductive
Center at Columbia University Medical
Center, specializes in the diagnosis and treat-
ment of male infertility. From his clinical per-
spective, other factors—including other
exposures—are more important than EDCs.
“The sky is not falling,” he says. “A lot of
times there’s extrapolation from high-dose
exposure to low-dose exposure. I think one of
the biggest culprits for the abnormalities we
see that’s been totally ignored is [increased]
parental age. Also, we need to look at things
we’re doing to ourselves before we start blam-
ing low-level chemicals. For example, what
does cigarette smoking do compared to Saran
Wrap? What about the diets we eat, the high-
fat intakes? Before we start blaming others,
we need to look at ourselves to determine the
impact of our lifestyles.”
Although plastic wrap may not be respon-
sible for human infertility, the scientific evi-
dence fueling growing concerns about the
effects of ambient environmental exposures
to EDCs cannot simply be dismissed.
“Vigilance is the key word here, because there
are so many chemicals out there,” says Burger.
“Understanding the effects of chemicals is a
three-pronged approach. It’s being sure that
we have wildlife models and people who are
watching wildlife populations to see quickly if
something detrimental happens. It’s having
really good epidemiological studies and vigi-
lance of people in various places. And it’s
backing those two up with laboratory science
immediately when a problem turns up, to try
to ascertain the cause quickly.” 
Ernie Hood
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Gender basis. In a study of the brain region known as the BSTc, which varies in size by sex, the
volume of the BSTc for male-to-female transsexuals was analogous to that seen in women, lead-
ing the authors to speculate that the findings “support the hypothesis that gender identity
develops as a result of an interaction between the developing brain and sex hormones.”
heterosexual male
homosexual male male-to-female transsexual
heterosexual female
Reprinted from: Zhou J-N, Hofman MA, Gooren LJG, Swaab DF. 1995. A sex difference in the human brain and its relation to
transsexuality. Nature 378:68–70.